KPV

What is the peptide KPV? Effects and definition of the tripeptide

KPV is a tripeptide made up of the three amino acids lysine, proline, and valine (Lys-Pro-Val). Amino acids are the smallest building blocks of proteins. KPV has anti-inflammatory properties and corresponds to the C-terminal end of the body's own hormone alpha-MSH. The peptide mimics some functions of the peptide hormone from the melanocortin family, which physiologically regulates skin pigmentation and inflammatory responses.

KPV currently has no medical approval from the US Food and Drug Administration (FDA) or the European Medicines Agency (EMA). It is neither a growth hormone nor a bodybuilding product. Since clinical human studies are completely lacking so far, the current state of research is based solely on cell cultures and animal experiments. You can find further information on related active substances in the peptide library.

How is KPV used? Forms of administration and application

There is no evidence-based standard for using KPV in humans, as the substance has not yet been studied in clinical human trials. Administration differs between preclinical research approaches and the unregulated practice found in user communities.

• Oral administration (studies): In preclinical animal experiments, mice received KPV at a dosage of 100 µM in their drinking water for a period of 8 days [1]. Newer experimental approaches use nanoparticle-based formulations for targeted drug release in the gut [2][3].
• Topical application (FDA briefing document): An FDA briefing document on compounded preparations documents gels and creams with a concentration of 0.1% KPV as a free base or acetate [4].
• Subcutaneous injection (gray market practice): User communities describe subcutaneous injections with dosages of 0.5 to 2 mg, which are not validated by scientific studies and do not constitute a medical recommendation.
• Oral capsules or drops (gray market practice): Capsules and drops sold on the gray market typically use amounts of 1 to 5 mg per unit without any clinical efficacy or safety testing.

The frequency of use described in forums ranges from once daily to three times a week. Due to the lack of controlled toxicological and clinical human testing, these dosage regimens have no scientific basis.

How is KPV mixed and dosed? Reconstitution from vial to use

For research purposes, KPV is supplied as a lyophilized powder in vials containing 5 mg or 10 mg of the active substance. It is reconstituted with liquids such as bacteriostatic water (BAC water) before use. You can find step-by-step instructions on handling and dissolving freeze-dried peptides in the Peptigraph guides.

Calculation example for documentation (not a recommendation): Dissolving a 5 mg vial of KPV in 2 ml of BAC water results in a calculated active substance concentration of 2.5 mg/ml.

For the topical formulation, a 0.1% preparation corresponds to exactly 1 mg of KPV per gram of carrier. A pea-sized amount of cream, about 0.5 g, therefore contains a calculated 0.5 mg of KPV. These values serve purely analytical purposes and do not constitute a dosing instruction.

Due to its short peptide structure of three amino acids, KPV is rapidly broken down enzymatically in blood plasma. Exact pharmacokinetic data on the half-life and metabolic rate in the human body have not yet been published.

How does KPV affect inflammatory processes in the body? Mechanism of action

KPV inhibits inflammatory processes primarily independently of receptors. The tripeptide enters the cell interior via the transporter PepT1 and blocks central signaling pathways there. This makes KPV's cellular mechanism of action fundamentally different from other hormones in the melanocortin group, which bind to membrane-bound receptors.

In the cytoplasm, KPV inhibits I-kappa-B kinase and thereby stabilizes the inhibitor protein I-kappa-B-alpha, preventing the transcription factor NF-kB from migrating into the cell nucleus. At the same time, KPV dampens MAP kinase signaling, which has been shown to reduce the release of the pro-inflammatory cytokines TNF-alpha, IL-1beta, and IL-6 [1].

What is the state of research on KPV for colitis and inflammation?

The scientific evidence on KPV consists exclusively of preclinical in-vitro studies and animal experimental data, while randomized clinical human trials do not exist. The focus of published research is on animal models of chronic inflammatory bowel disease (IBD, such as ulcerative colitis).

In mouse models of dextran sulfate sodium-induced colitis (DSS colitis), oral administration of KPV (100 µM in drinking water for 8 days) lowered inflammatory markers [1]. A 2017 publication showed that hyaluronic acid-functionalized nanoparticles release KPV specifically in the gut and reduce intestinal inflammation [2]. In 2021, another study demonstrated that a hydrogel protects KPV from premature degradation and improves inflammatory parameters in rats with TNBS-induced colitis [3].

Experimental work also describes accelerated wound healing processes on the cornea of the eye and in cultured skin models. Study results on the parent hormone alpha-MSH in contact dermatitis cannot be directly transferred to KPV; experimental findings on antimicrobial properties remain inconsistent.

What are the risks and side effects of using KPV?

There are no systematic clinical data on adverse drug reactions, toxicity, or contraindications of KPV in humans. The absence of published side effect reports does not prove safety; it results from the lack of standardized toxicological human testing.

Typical risk factors in unregulated self-administration on the gray market include:

• Incorrect reconstitution: Inaccurate mixing ratios with BAC water lead to deviating active substance concentrations and dosing errors.
• Unsuitable solvents: Using unpreserved sterile water for multiple withdrawals promotes bacterial contamination in the solution.
• Hygiene deficiencies: Failing to wipe-disinfect the vials or reusing needles significantly increases the risk of infection.
• Unsubstantiated dosage regimens: Adopting community values without clinical validation creates a false sense of security.

Unregulated peptides purchased online carry significant risks of contamination or incorrect labeling. The vendor radar helps you methodically review certificates of analysis and suppliers to protect yourself from dubious sources.

Is KPV approved as a drug? Legal status and FDA classification

KPV is not approved as a finished drug product either by the EMA in the European Union or by the FDA in the USA. Since it is often declared as a research chemical, medical use in humans is legally excluded.

In September 2023, the FDA placed KPV in category 2 of the 503A bulks list ("Significant Safety Risks"), which prohibited compounding pharmacies in the USA from making the preparation. In April 2026, the FDA formally removed the peptide from this list after the applicants withdrew their nomination, without this being accompanied by a declaration of safety [4].

On July 23, 2026, the FDA's Pharmacy Compounding Advisory Committee (PCAC) recommended, with a vote of 8 to 6 (with 1 abstention), that KPV (free base and acetate) be added to the 503A bulks list [5]. This advisory vote went against the scientific opinion of the FDA reviewers, is not legally binding, and requires a formal notice-and-comment process. Until this process is completed, KPV remains not approved for compounded drugs in the USA.

Commercial advertising claims about alleged human studies with KPV lack a scientific basis. Reliable clinical data on efficacy and safety in humans are still not available.